Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2018; 8(21):6070-6087. doi:10.7150/thno.27275 This issue Cite

Research Paper

T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target

Kristine E. Mayer1*, Sabine Mall1,2*, Nahid Yusufi3, Dario Gosmann1, Katja Steiger2,4, Lisa Russelli3, Henrique de Oliviera Bianchi1, Stefan Audehm1, Ricarda Wagner1, Eva Bräunlein1, Anja Stelzl1, Florian Bassermann1,2, Wilko Weichert2,4, Wolfgang Weber2,3, Markus Schwaiger2,3, Calogero D'Alessandria3, Angela M. Krackhardt1,2✉

1. Clinic and Policlinic for Internal Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
2. German Cancer Consortium (DKTK), partner-site Munich; and German Cancer Research Center (DKFZ), Heidelberg, Germany
3. Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
4. Institute of Pathology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
*K.E.M. and S.M. contributed equally to the work

✉ Corresponding author: Angela M. Krackhardt, Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. E-mail: angela.krackhardtde Phone: +49 (0) 89-4140-4124 Fax: +49 More

Citation:
Mayer KE, Mall S, Yusufi N, Gosmann D, Steiger K, Russelli L, Bianchi HdO, Audehm S, Wagner R, Bräunlein E, Stelzl A, Bassermann F, Weichert W, Weber W, Schwaiger M, D'Alessandria C, Krackhardt AM. T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target. Theranostics 2018; 8(21):6070-6087. doi:10.7150/thno.27275. https://www.thno.org/v08p6070.htm
Other styles

File import instruction

Abstract

Graphic abstract

Cancer immunotherapy has proven high efficacy in treating diverse cancer entities by immune checkpoint modulation and adoptive T-cell transfer. However, patterns of treatment response differ substantially from conventional therapies, and reliable surrogate markers are missing for early detection of responders versus non-responders. Current imaging techniques using 18F-fluorodeoxyglucose-positron-emmission-tomograpy (18F-FDG-PET) cannot discriminate, at early treatment times, between tumor progression and inflammation. Therefore, direct imaging of T cells at the tumor site represents a highly attractive tool to evaluate effective tumor rejection or evasion. Moreover, such markers may be suitable for theranostic imaging.

Methods: We mainly investigated the potential of two novel pan T-cell markers, CD2 and CD7, for T-cell tracking by immuno-PET imaging. Respective antibody- and F(ab´)2 fragment-based tracers were produced and characterized, focusing on functional in vitro and in vivo T-cell analyses to exclude any impact of T-cell targeting on cell survival and antitumor efficacy.

Results: T cells incubated with anti-CD2 and anti-CD7 F(ab´)2 showed no major modulation of functionality in vitro, and PET imaging provided a distinct and strong signal at the tumor site using the respective zirconium-89-labeled radiotracers. However, while T-cell tracking by anti-CD7 F(ab´)2 had no long-term impact on T-cell functionality in vivo, anti-CD2 F(ab´)2 caused severe T-cell depletion and failure of tumor rejection.

Conclusion: This study stresses the importance of extended functional T-cell assays for T-cell tracer development in cancer immunotherapy imaging and proposes CD7 as a highly suitable target for T-cell immuno-PET imaging.

Keywords: T-cell imaging, cancer immunotherapy, T-cell function, immuno-PET

Citation styles

APA
Mayer, K.E., Mall, S., Yusufi, N., Gosmann, D., Steiger, K., Russelli, L., Bianchi, H.d.O., Audehm, S., Wagner, R., Bräunlein, E., Stelzl, A., Bassermann, F., Weichert, W., Weber, W., Schwaiger, M., D'Alessandria, C., Krackhardt, A.M. (2018). T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target. Theranostics, 8(21), 6070-6087. https://doi.org/10.7150/thno.27275.

ACS
Mayer, K.E.; Mall, S.; Yusufi, N.; Gosmann, D.; Steiger, K.; Russelli, L.; Bianchi, H.d.O.; Audehm, S.; Wagner, R.; Bräunlein, E.; Stelzl, A.; Bassermann, F.; Weichert, W.; Weber, W.; Schwaiger, M.; D'Alessandria, C.; Krackhardt, A.M. T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target. Theranostics 2018, 8 (21), 6070-6087. DOI: 10.7150/thno.27275.

NLM
Mayer KE, Mall S, Yusufi N, Gosmann D, Steiger K, Russelli L, Bianchi HdO, Audehm S, Wagner R, Bräunlein E, Stelzl A, Bassermann F, Weichert W, Weber W, Schwaiger M, D'Alessandria C, Krackhardt AM. T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target. Theranostics 2018; 8(21):6070-6087. doi:10.7150/thno.27275. https://www.thno.org/v08p6070.htm

CSE
Mayer KE, Mall S, Yusufi N, Gosmann D, Steiger K, Russelli L, Bianchi HdO, Audehm S, Wagner R, Bräunlein E, Stelzl A, Bassermann F, Weichert W, Weber W, Schwaiger M, D'Alessandria C, Krackhardt AM. 2018. T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target. Theranostics. 8(21):6070-6087.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use